| AACR 2019 Roundup: Notes from a Weekend of Early Stage Cancer Results | Ben Fidler | 04/03/19 | National |
| The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski | Ben Fidler | 03/11/19 | National |
| Acetylon Crafts New Buyout Deal With Celgene, Spins Out Startup Regenacy | Ben Fidler | 12/02/16 | Boston |
| Celgene Passes on Acetylon as Another Option-to-Buy Deal Flames Out | Ben Fidler | 08/08/16 | Boston |
| West Coast Biotech Roundup: Bock, Celladon, Arivale, Conkwest & More | Alex Lash | 06/26/15 | San Diego |
| East Coast Biotech Roundup: NJ Blues, Genzyme, Amicus, Biogen & More | Ben Fidler | 08/25/14 | Boston |
| Merrimack Heads to FDA as Pancreatic Cancer Drug Succeeds in Phase 3 | Ben Fidler | 05/01/14 | Boston |
| Brushing Off Clinical Setback, Cerulean Tees Up $75M IPO | Ben Fidler | 03/10/14 | Boston |
| East Coast Biotech Roundup: Gerngross, Akili, Intercept, & More | Ben Fidler | 01/10/14 | Boston |
| East Coast Life Sciences Roundup: Genocea, Biogen, OvaScience, & More | Ben Fidler | 09/13/13 | Boston |
| Investors to Get $300M as FDA Approves Celgene Drug For Pancreatic Cancer | Ben Fidler | 09/06/13 | New York |
| Cerulean Pharma Arrives at Turning Point With Cancer Drug | Luke Timmerman | 03/06/13 | Boston |
